Actively Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-04-17
220
Participants Needed
1
Research Sites
377 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
CONDITIONS
Official Title
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent
- Age 18 to 75 years, male or female
- ECOG performance status of 0 or 1
- Histopathologically confirmed unresectable locally advanced or metastatic low or medium grade (G1 or G2) gastrointestinal neuroendocrine tumors (GEP-NETs)
You will not qualify if you...
- Known central nervous system metastasis, except stable brain metastases treated by radiotherapy or surgery with no symptoms for at least 24 weeks
- Uncontrolled heart disease or clinical symptoms
- Diabetes with fasting blood glucose greater than 2 times the upper limit of normal not controlled by optimal treatment
- Severe urinary incontinence, hydronephrosis, severe urination dysfunction, or use of an indwelling catheter for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
Research Team
X
Xueying Zheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here